Tacrolimus
| 證據等級: L5 | 預測適應症: 3 個 |
目錄
Tacrolimus: From Atopic Dermatitis to Seborrheic Dermatitis
One-Sentence Summary
Tacrolimus ointment (Protopic®) is an established topical calcineurin inhibitor for atopic dermatitis. The TxGNN model predicts it may also be effective for Seborrheic Dermatitis, with 2 clinical trials and 20 publications currently supporting this direction — much of which already reflects real-world off-label and even on-label dermatology practice.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Atopic Dermatitis (topical formulation; per literature evidence — no formal license/regulatory record available in this evidence pack) |
| Predicted New Indication | Seborrheic Dermatitis |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L2 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the structured drug record (original_moa: [Data Gap]). However, the supporting literature within this evidence pack consistently describes tacrolimus as a calcineurin inhibitor: it suppresses antigen-specific T-cell activation and downregulates the pro-inflammatory cytokine cascade (PMID 15819596, 12125507, 11145792). This anti-inflammatory, non-steroidal mechanism is the basis for its established use in topical treatment of atopic dermatitis (Protopic ointment), where it has been studied in over 16,000 patients across 20+ years of trials referenced here (e.g., NCT00480896, NCT00480610, NCT02601703).
Seborrheic dermatitis (SD) shares a similar inflammatory, T-cell-mediated pathophysiology with atopic dermatitis, occurring in sebaceous-rich areas and often exacerbated by Malassezia yeast colonization (PMID 16094289, 28685715). Because tacrolimus’s anti-inflammatory action is not steroid-dependent, it avoids the skin atrophy and rebound risk associated with long-term topical corticosteroid use — a specific concern in facial SD, where corticosteroids are otherwise first-line (PMID 19213227, 27804089). This mechanistic overlap explains why dermatologists have already tested tacrolimus in SD for over two decades, from early open-label pilot work (PMID 12833030, 2003) through to multicenter randomized controlled trials (PMID 33010323, JAAD 2021).
Two additional TxGNN-predicted indications from the same evidence pack — parapsoriasis (rank 2, score 99.24%) and general dermatitis (rank 3, score 99.17%) — reinforce this signal. Both are also T-cell-mediated inflammatory dermatoses with published case reports and reviews supporting topical tacrolimus use (e.g., PMID 15149526, 12823321 for pityriasis lichenoides/parapsoriasis). Taken together, the model is largely re-identifying and quantifying a coherent, mechanistically consistent cluster of inflammatory skin conditions already responsive to calcineurin inhibition, rather than proposing an unrelated new indication.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT02004860 | Phase 3 | Completed | 120 | Evaluated tacrolimus ointment (Protopic®) for maintenance treatment of severe facial seborrheic dermatitis in adults, aiming to reduce relapse frequency and prolong remission versus topical steroids. |
| NCT01591070 | Phase 4 | Completed | 104 | Assessed whether proactive once/twice-weekly application of 0.1% tacrolimus ointment maintains remission and reduces exacerbation incidence in adult facial SD. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 33010323 | 2021 | RCT | J Am Acad Dermatol | Multicenter, double-blind RCT: tacrolimus 0.1% vs. ciclopiroxolamine 1% for maintenance therapy in severe facial SD — first long-term maintenance comparison in this disease. |
| 22101215 | 2012 | RCT | J Am Acad Dermatol | Single-blind RCT comparing hydrocortisone 1% ointment vs. tacrolimus 0.1% ointment for facial SD in adults. |
| 24171300 | 2013 | RCT | Ann Parasitol | Compared sertaconazole 2% cream vs. tacrolimus 0.03% cream in 60 SD patients. |
| 37067129 | 2023 | RCT | Indian J Dermatol Venereol Leprol | Oral itraconazole (2 days) plus topical tacrolimus vs. topical tacrolimus alone for maintenance treatment of SD in Vietnam. |
| 26512166 | 2015 | Clinical study | Ann Dermatol | Maintenance therapy of facial SD with 0.1% tacrolimus ointment, applying the intermittent maintenance model established in atopic dermatitis. |
| 12833030 | 2003 | Open-label pilot | J Am Acad Dermatol | First pilot study of 0.1% tacrolimus in 18 SD patients; 61% achieved complete clearance within 28 days. |
| 27804089 | 2017 | Systematic Review | Am J Clin Dermatol | Systematic review of topical treatments (antifungals, keratolytics, corticosteroids) for facial SD, situating calcineurin inhibitors among first-line options. |
| 19222250 | 2009 | Review | Am J Clin Dermatol | Review of pathophysiology, safety, and efficacy of topical calcineurin inhibitors specifically in SD. |
| 19213227 | 2009 | Review | J Drugs Dermatol | Overview of facial SD status and therapeutic horizons, including sebaceous/hormonal and Malassezia-related mechanisms. |
| 11770914 | 2001 | Review | Semin Cutan Med Surg | Early review of topical tacrolimus/pimecrolimus future directions, including SD, psoriasis, and lichen planus. |
US Market Information
Tacrolimus is recorded as not marketed in this jurisdiction, with 0 license/NDA records in the evidence pack. No authorization table can be generated from taiwan_regulatory.licenses.
Safety Considerations
Please refer to the package insert for safety information.
Note: The evidence pack flags a blocking data gap (DG001) — TFDA/FDA label warnings and contraindications are unavailable — which prevents a formal safety (S1) assessment at this time. Drug-drug interaction data was also queried but not found.
Conclusion and Next Steps
Decision: Hold
Rationale: Efficacy evidence for seborrheic dermatitis is reasonably strong for a repurposing candidate — one completed Phase 3 RCT, one completed Phase 4 maintenance study, and multiple additional RCTs/reviews spanning two decades (L2 evidence level) — and the mechanism is biologically coherent with tacrolimus’s established anti-inflammatory action in atopic dermatitis. However, the drug is not currently marketed in this jurisdiction, and critical safety data (label warnings, contraindications, DDI) is completely missing, blocking initial safety review.
To proceed, the following is needed:
- TFDA/FDA package insert data (warnings, contraindications) — resolve DG001 (Blocking)
- Confirmed mechanism of action from DrugBank — resolve DG002
- Drug-drug interaction profile for topical calcineurin inhibitors
- Clarification of regulatory/market status and any pathway for formulation-specific approval (topical ointment) for this indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.